BioSpace News Archive

Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.

Last week, HHS Secretary Alex Azar assumed all final authority in deciding new rules regarding food, medical devices and new medications.

The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.

Swiss pharma giant Roche acquired Ireland’s Inflazome and its NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases for €380 million (about $451 million) in an upfront payment.

The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.

Legend’s CEO and Board Chairman, Fangliang “Frank” Zhange, was placed on “residential surveillance” by PRC law enforcement.

Competition for resources is growing, and the usual supply chain partners may not have available capacity in the preferred timeframe.

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management and scientific team will participate at upcoming scientific and investor conferences. 56 th European Association for the Study of Diabetes (EASD) An

Amazfit Band 5, a smart wrist band, launched as the latest offering of Huami to the excellence of Amazfit wearable lineup.